Themis Medicare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹90 Cr +15.1% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
TM

Themis Medicare Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Themis Medicare Q2 FY26: Revenue ₹77.99 Cr, Net loss ₹3.62 Cr

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹78Cr
−33.3% YoY
−20.1% QoQ
Net profit
−₹4Cr
Q2 FY25: ₹14 Cr
Margin
−3.97%
−18.6 pp YoY
+6.5 pp QoQ

Based on Themis Medicare Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹118
Market cap₹1.1K Cr

The short version

Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) - H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9) - API business showed growth in Quarter (Q2 FY26) Financials vs Q2 FY25: - EBITDA: ₹(3.09) Cr, down 118.0% YoY (Q2 FY25: ₹17.13 Cr) - EBITDA Margin: (3.96)%, down from 14.6% YoY - PAT: ₹(3.62) Cr, down 125.3% YoY (Q2 FY25: ₹14.29 Cr) - PAT Margin: (4.64)%, down from 12.2% YoY - Operating Margin: - EBITDA margin for Q2 FY26 is negative at (3.96)%.

From Themis Medicare Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8)
  • H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9)
  • API business showed growth in the half year with a 31% YoY increase; Trade business increased 4% (Page 5)
  • Formulations business faced headwinds negatively impacting top line (Page 8)
  • Management expects positive regulatory developments by March 2026 (Page 5)

2 more points from Themis Medicare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

While it highlights: - State-of-the-art manufacturing facilities in India (1 formulations and 2 API facilities: Synthetic + Biotech) at Haridwar, Hyderabad, and Vapi (page 14), - Strong R&D investments (around Rs. 13-14 Cr. annually, with plans continuing through FY24-25) (page 15), - Focus on expansion in new Rest of World (RoW) markets in Phase I (0-3 years) and regulated markets in Phase II (3-5 years) (page 18),

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Key points from the presentation include: - Financial highlights feature net revenue, EBITDA, PAT for various periods. - Strategy and growth outlooks focus on market expansion and product development rather than order metrics.

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Themis Medicare Ltd Q2 FY26 results — key figures

Themis Medicare Ltd Q2 FY26 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY26
Revenue78
Operating profit (EBITDA)-3
Operating margin-4%
Profit before tax-5
Net profit (PAT)-4
EPS (₹)-0.39

Source: Themis Medicare Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Themis Medicare Ltd Q2 FY26 results?

Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) - H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9) - API business showed growth in Quarter (Q2 FY26) Financials vs Q2 FY25: - EBITDA: ₹(3.09) Cr, down 118.0% YoY (Q2 FY25: ₹17.13 Cr) - EBITDA Margin: (3.96)%, down from 14.6% YoY - PAT: ₹(3.62) Cr, down 125.3% YoY (Q2 FY25: ₹14.29 Cr) - PAT Margin: (4.64)%, down from 12.2% YoY - Operating Margin: - EBITDA margin for Q2 FY26 is negative at (3.96)%.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.